Licensed worldwide rights to develop and commercialize ALPHA-1062IN in TBI and related disorders from Alpha Cognition, Inc. ALPHA-1062IN: Potential first treatment for Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) - Plans to develop and commercialize ALPHA-1062IN in TBI and related di...
Use this information to figure out if this company is an ideal customer for you.
Dallas
Alpha Seven Therapeutics Inc.'s CEO is Michael McFadden
Alpha Seven Therapeutics Inc.'s HQ is located at Dallas
Alpha Seven Therapeutics Inc.'s official website is alphaseventbi.com
Alpha Seven Therapeutics Inc.'s revenue is $1M - $5M
Alpha Seven Therapeutics Inc. has 11 - 50 employees
Alpha Seven Therapeutics Inc. is in the industry of: Pharmaceuticals